Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar
Alnylam investors $ALNY can now start breathing again.
The big Cambridge, MA-based biotech says that their Phase III study of patisiran — partnered with Sanofi — scored a positive hit for the primary as well as all secondary endpoints in treating rare cases of hereditary ATTR amyloidosis with polyneuropathy.
The score sets up Alnylam’s first new drug application with the FDA before the end of this year with a European filing following soon after, while Sanofi gears up for a slate of applications around the globe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.